September 29, 2020 11:17 AM EDTUpdated 02:08 PM
R&D

My­ovant shows dis­ap­point­ing prostate can­cer da­ta on the way to the FDA, stock sinks

Max Gelman

Senior Editor

My­ovant $MY­OV has been prep­ping re­l­u­golix for ad­vanced prostate can­cer over the last sev­er­al months, look­ing to im­prove up­on the old stan­dard in Ab­b­Vie …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times